Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(PF 04691502; PF04691502)
PF-04691502 Chemical Structure
|Product name: PF-04691502|
|Cat. No.: HY-15177|
PF-04691502 is an ATP-competitive PI3K(α/β/δ/γ)/mTOR dual inhibitor with Ki of 1.8 nM/2.1 nM/1.6 nM/1.9 nM and 16 nM, little activity against either Vps34, AKT, PDK1, p70S6K, MEK, ERK, p38, or JNK.
IC50 value: 1.8 nM/2.1 nM/1.6 nM/1.9 nM(PI3Kα/β/δ/γ); 16 nM(mTOR)
PF-04691502 is an ATP-competitive PI3K/mTOR dual inhibitor with IC50 of 32 nM. PF-04691502 is also an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor PF-04691502 inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K. PF-04691502 is currently in Phase II clinical trials in patients with recurrent endometrial cancer and Breast Cancer. A Phase II clinical trials in patients with solid tumors has been completed.
|M.Wt||425.48||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
DMSO > 60 mg/mL Ethanol > 60 mg/mL
|1 mg||5 mg||10 mg|
|1 mM||2.3503 mL||11.7514 mL||23.5029 mL|
|5 mM||0.4701 mL||2.3503 mL||4.7006 mL|
|10 mM||0.2350 mL||1.1751 mL||2.3503 mL|
|Product Name||Sponsor Only||Condition||Start Date||End Date||Phase||Last Change Date|
|PF-04691502||Pfizer Inc||Metastatic breast cancer||31-JAN-13||30-APR-15||Phase 2||11-SEP-13|
|Pfizer Inc||Advanced solid tumor||31-DEC-09||30-APR-12||Phase 1||31-MAY-12|
|Pfizer Inc||Endometrioid carcinoma||01-JAN-12||31-MAY-14||Phase 2||28-NOV-13|
|Pfizer Inc||Breast tumor||31-MAR-12||31-DEC-12||Phase 2||26-DEC-12|
|Pfizer Inc||Advanced solid tumor||31-OCT-11||30-NOV-14||Phase 1||06-NOV-13|
. Kinross KM, Brown DV, Kleinschmidt M et al. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer. Mol Cancer Ther. 2011 Aug;10(8):1440-9.
. Simmons BH, Lee JH, Lalwani Ket al. Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice. Cancer Chemother Pharmacol. 2012 Aug;70(2):213-20.
3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3K(gamma) with IC50 of 25 (mu)M and 60 (mu)M.
A66 is a potent and specific p110(alpha) inhibitor with IC50 of 32 nM, >100 fold selectivity for p110(alpha) over other class-I PI3K isoforms.
Acalisib (GS-9820) is a potent and selective inhibitor of PI3K(delta) with IC50 value of 12.7 nM.
AMG319 is a potent and selective PI3K(delta) inhibitor with IC50 of 18 nM, also inhibits PI3K(gamma) with IC50 of 850 nM.
AS-252424 is a potent and selective inhibitor of PI3K(gamma) with IC50 of 33 nM; >10 fold selectivity for PI3K(gamma) versus PI3K(alpha).
AS-605240 is a potent and selective inhibitor of PI 3-kinase (gamma) (PI3K(gamma)) (IC50 = 8 nM). AS-605240 displays 30-fold selectivity over PI3K(delta) and PI3K(beta) and 7.5-fold selectivity over PI3K(alpha).
AZD6482 is a PI3K(beta) inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3K(beta) than PI3K(delta), PI3K(alpha) and PI3K(gamma).
AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM with excellent selectivity (～1,000-fold) against PI3K isoforms and ATM/DNA-PK.
AZD8835 is a potent and selective inhibitor of PI3K(delta) and PI3K(alpha)with IC50 of 5.7 nM and 6.2 nM, with selectivity against PI3K(beta) (IC50 431 nM) and PI3K(gamma) (IC50 90 nM).
AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM; highly selective against multiple PI3K isoforms ((alpha)/(beta)/(gamma)/(delta)).